People: Pacira Pharmaceuticals Inc (PCRX.O)
PCRX.O on Nasdaq
29.44USD
17 May 2013
29.44USD
17 May 2013
Price Change (% chg)
$0.27 (+0.93%)
$0.27 (+0.93%)
Prev Close
$29.17
$29.17
Open
$29.33
$29.33
Day's High
$29.69
$29.69
Day's Low
$29.26
$29.26
Volume
371,250
371,250
Avg. Vol
490,763
490,763
52-wk High
$30.94
$30.94
52-wk Low
$9.81
$9.81
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Fred Middleton |
Independent Chairman of the Board | ||
David Stack |
60 | 2007 | President, Chief Executive Officer, Director |
James Scibetta |
47 | 2008 | Chief Financial Officer |
Lauren Riker |
33 | 2012 | Principal Accounting Officer |
Taunia Markvicka |
43 | 2011 | Vice President - Commercial |
John Pratt |
68 | 2012 | General Manager - San Diego Facility |
Gary Patou |
2009 | Chief Medical Officer | |
Laura Brege |
54 | 2011 | Independent Director |
Luke Evnin |
2006 | Independent Director | |
Paul Hastings |
52 | 2011 | Independent Director |
John Longenecker |
64 | 2007 | Independent Director |
Gary Pace |
2008 | Independent Director | |
Andreas Wicki |
53 | 2006 | Independent Director |
Biographies
| Name | Description |
|---|---|
Fred Middleton |
Mr. Fred A. Middleton serves as an Independent Chairman of the Board of Pacira Pharmaceuticals Inc. He has served as director since inception in December 2006. Since 1987, he has been a general partner/managing director of Sanderling Ventures, a firm specializing in biomedical venture capital. From 1984 through 1986, he was the managing general partner of Morgan Stanley Ventures, an affiliate of Morgan Stanley & Co. Earlier in his career, Mr. Middleton was part of the of the founding management team at Genentech, Inc., a biotechnology company, serving there from 1978 through 1984 as vice president of finance and corporate development, and chief financial officer. During the last 30 years, he has participated in active management roles and as an investor and director in over 20 start-up biomedical companies. He currently serves as chairman of the board of Stereotaxis, Inc. (NASDAQ: STXS), a medical device company that markets magnetically guided robotic surgery systems in cardiology. He also currently serves as a board member of Cardionet, Inc. (NASDAQ: BEAT), a company that markets devices and services for wireless 24/7 real time monitoring of patients. He also serves as a director of seven other privately-held biomedical companies, engaged in the development of therapeutic and diagnostic products in healthcare. Mr. Middleton received a B.S. degree in chemistry from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School. |
David Stack |
Mr. David M. Stack serves as President, Chief Executive Officer, Director of Pacira Pharmaceuticals Inc., since November 2007. Mr. Stack has been a managing director of MPM Capital since 2005 and a managing partner of Stack Pharmaceuticals, Inc. since 1998. From 2001 to 2004, he was president and chief executive officer of The Medicines Company (NASDAQ: MDCO). Previously, Mr. Stack was president and general manager at Innovex, Inc. He was vice president, business development/marketing at Immunomedics from 1993 until 1995. Prior to that, he was with Roche Laboratories in positions of responsibility from 1981 until 1993, including, business development and planning, infectious disease, oncology, and virology. He currently serves as a member of the board of directors of PepTx, Inc. He was a member of the boards of directors of Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) from 2006 to 2010 and BioClinica, Inc. (NASDAQ: BIOC) from 1999 to 2010. Mr. Stack holds a B.S. in pharmacy from Albany College of Pharmacy and a B.S. in Biology from Siena College. |
James Scibetta |
Mr. James S. Scibetta serves as Chief Financial Officer of Pacira Pharmaceuticals Inc., since August 2008. Prior to that, Mr. Scibetta was chief financial officer of Bioenvision, Inc. (NASDAQ: BIVN) from 2006 until its acquisition by Genzyme, Inc. in 2007. From 2001 to 2006, Mr. Scibetta was executive vice president and chief financial officer of Merrimack Pharmaceuticals, Inc., and he was a member of the board of directors of Merrimack from 1998 to 2004. Mr. Scibetta formerly served as a senior investment banker at Shattuck Hammond Partners, LLC and PaineWebber Inc., providing capital acquisition, merger and acquisition, and strategic advisory services to healthcare companies. He currently serves as chairman of the board and audit committee of Nephros, Inc. (NASDAQ: NEPH). He was a member of the board of directors of Labopharm Inc. (NASDAQ:DDSS, Toronto Stock Exchange: DDS) from 2001 to 2008. Mr. Scibetta holds a B.S. in physics from Wake Forest University, and an M.B.A. in finance from the University of Michigan. He completed executive education studies in the Harvard Business School Leadership & Strategy in Pharmaceuticals and Biotechnology program. |
Lauren Riker |
Ms. Lauren Riker has been appointed as Principal Accounting Officer of Pacira Pharmaceuticals, Inc., effective March 21, 2012. She has served as the company's Executive Director, Accounting and Financial Reporting since May 2011. Prior to joining the company, Ms. Riker served as Senior Director of Financial Reporting at Ikaria, Inc. (“Ikaria”), a private critical care biopharmaceutical company, from April 2008 to April 2011, where she was responsible for the oversight, monitoring and review of Ikaria’s financial reporting, technical accounting and stock-based compensation program. From December 2004 to February 2008 Ms. Riker served as the Controller and later the Chief Accounting Officer of Bioenvision, Inc., (“Bioenvision”) a publicly traded biotechnology company. Her responsibilities at Bioenvision included preparation of its financial statements and disclosures in accordance with United States generally accepted accounting principles and the reporting requirements of the SEC and implementation of internal controls and procedures in compliance with Sarbanes-Oxley. From 2000 to 2004, Ms. Riker worked at KPMG in the Information, Communication and Entertainment sector where she held positions of increasing responsibility, including audit manager. Ms. Riker holds a B.S. in accounting from Boston College and an M.B.A. from Columbia Business School. |
Taunia Markvicka |
Dr. Taunia Markvicka, Pharm. D. has been Vice President - Commercial of Pacira Pharmaceuticals Inc. She served as Vice President, Commercial since November 2010. Dr. Markvicka is a partner at Stack Pharmaceuticals, Inc., a commercialization, marketing, and strategy firm, in addition to her role at Pacira. Her most recent pharmaceutical positions include serving as a franchise marketing director at The Medicines Company for the cardiovascular and hematology acute care products. Previously, Dr. Markvicka was Marketing Director at Watson Pharmaceuticals, where she oversaw marketing, medical marketing and new product planning for urology and general products. She was also with Advantage Healthcare, a strategic marketing and new product planning firm, as a Vice President for two years. She joined the pharmaceutical industry, initially taking a two year post-doctoral fellowship position with Sandoz (now Novartis). Dr. Markvicka holds a Doctor of Pharmacy degree from the University of Nebraska, an MBA from St. Josephs University, and she maintains her license as a registered pharmacist. |
John Pratt |
Mr. John Pratt has been General Manager - San Diego Facility of Pacira Pharmaceuticals, Inc., since January 2012. Prior to joining the Company, Mr. Pratt was a general manager of Amylin Ohio LLC (“Amylin Ohio”), a subsidiary of Amylin Pharmaceuticals, from 2006 to 2011. In that role, Mr. Pratt managed a 305-person operations team while simultaneously directing Amylin Ohio’s commercial operations and leading the design, construction and FDA acceptance of a 550,000 square foot, state-of-the-art manufacturing, inspection and packaging facility. Prior to his employment with Amylin Ohio, Mr. Pratt was employed by Novo Nordisk, where he held various senior management roles related to manufacturing operations and quality control. Mr. Pratt has a B.S. in Microbiology/Chemistry from the University of Montana and took post-graduate coursework at the University of Washington. |
Gary Patou |
Dr. Gary Patou, M.D., serves as Chief Medical Officer of Pacira Pharmaceuticals Inc., since March 2009. Dr. Patou has been a managing director of MPM Capital since 2005. He has served as chief medical officer of the following MPM Capital portfolio companies: Peplin, Ltd. (ASX: PLI), from June 2006 to April 2007 and from June 2008 to May 2009, Cerimon Pharmaceuticals, Inc., from June 2005 to June 2006, and Oscient Pharmaceuticals, Inc., from February 2004 to April 2005. Dr. Patou currently spends part of his time as the acting chief executive officer of Cerimon Pharmaceuticals, Inc. From 2001 to 2004, he was president of Genesoft and from 1995 to 2000, Dr. Patou worked at SmithKline Beecham Pharmaceuticals, now a unit of GlaxoSmithKline (LSE: GSK), where he held positions of increasing responsibility including senior vice president and director, project and portfolio management. From 1991 to 1995, he held increasing senior, director level positions at Vernalis (LSE:VER), formerly British Biotechnology. He currently serves as a member of the board of directors of Xenon Pharmaceuticals, Inc. He served as a member of the board of directors of Oscient Pharmaceuticals Corporation (NASDAQ: OSCI) from 2005 to 2008. Dr. Patou has held a number of academic appointments at University College & Middlesex School of Medicine in London and holds an M.D. from University College, London. |
Laura Brege |
Ms. Laura A. Brege serves as an Independent Director of Pacira Pharmaceuticals Inc., since June 2, 2011. Ms. Brege recently retired from her position as executive vice president, corporate affairs for Onyx Pharmaceuticals, Inc. and has served as our director since June 2011. Previously, Ms. Brege held the roles of chief operating officer and executive vice president and chief business officer for Onyx. Prior to joining Onyx in 2006, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm, and senior vice president and chief financial officer at COR Therapeutics, Inc. Ms. Brege currently serves as a director of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD). She previously served as a member of the board of directors of Angiotech Pharmaceuticals Inc. from 2007 to 2011. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago. |
Luke Evnin |
Dr. Luke B. Evnin, Ph.D., serves as an Independent Director of Pacira Pharmaceuticals Inc., since December 2006. Dr. Evnin has served as a general partner or managing director at MPM Capital since co-founding the firm in 1998. Prior to joining MPM, Dr. Evnin was at Accel Partners from 1990 to 1997 serving as general partner from 1994 to 1997. Dr. Evnin has served as director of several public companies, including EnteroMedics Inc. (NASDAQ: ETRM), Epix Medical, Inc. (NASDAQ: EPIX), Metabasis Therapeutics, Inc. (NASDAQ: MBRX), Oscient Pharmaceuticals Corporation (NASDAQ: OSCI), Restore Medical, Inc., Otix Global, Inc. (NASDAQ: OTIX), formerly known as Sonic Innovations, Inc. and Signal Pharmaceuticals, Inc. and is currently or has been a director of several private healthcare companies in both the medical device and biopharmaceutical sectors. Dr. Evnin earned his Ph.D. in biochemistry from the University of California, San Francisco and his A.B. in molecular biology from Princeton University. |
Paul Hastings |
Mr. Paul J. Hastings serves as Independent Director of Pacira Pharmaceuticals Inc., since June 2, 2011. Mr. Hastings has served as president and chief executive officer of OncoMed Pharmaceuticals, Inc. since January 2006. Prior to joining OncoMed, Mr. Hastings was president and chief executive officer of QLT, Inc. Before this role, Mr. Hastings served as president and chief executive officer of Axys Pharmaceuticals, Inc., which was acquired by Celera Corporation in 2001. Prior to Axys, Mr. Hastings was president of Chiron Biopharmaceuticals and also held a variety of management positions of increasing responsibility at Genzyme Corporation, including president of Genzyme Therapeutics Europe and president of Worldwide Therapeutics. Mr Hastings was Chairman of the Board of Proteolix, Inc. from 2008 to 2010 (sold to Onyx) and was a member of the board of directors of ViaCell, Inc. from 2000 to 2007 (sold to Perkin Elmer). Mr. Hastings currently serves as chairman of the board of the Bay Area Biosciences Association (Bay Bio) and is Vice Chair of the Emerging Companies Section of the Biotechnology Industry Organization. He received a Bachelor of Science degree in pharmacy from the University of Rhode Island. |
John Longenecker |
Dr. John P. Longenecker, Ph.D., serves as an Independent Director of Pacira Pharmaceuticals Inc., since July 2007. Dr. Longenecker currently serves as president and chief executive officer of HemaQuest Pharmaceuticals, Inc. From December 2009 to March 2010, Dr. Longenecker served as the president and chief executive officer of VitreoRetinal Technologies Inc. From February 2002 to January 2009, Dr. Longenecker was the president and chief executive officer and a member of the board of directors of Favrille, Inc. In 1992, Dr. Longenecker joined DepoTech as senior vice president of research, development and operations and then served as president and chief operating officer from February 1998 to March 1999. Under Dr. Longenecker's leadership, DepoTech took its lead product, DepoCyt(e), from early pre-clinical research and development through to commercial launch. Following SkyePharma PLC's acquisition of DepoTech in 1999, Dr. Longenecker served as president for the U.S. operations of SkyePharma, Inc. and as a member of the executive committee for SkyePharma PLC. From 1982 to 1992, Dr. Longenecker was at Scios Inc. (Cal Bio), a biotechnology company where he served as vice-president and director of development. Dr. Longenecker was also a director of a number of Cal Bio subsidiaries during this period including Meta Bio and Karo Bio. Dr. Longenecker holds a B.S. in chemistry from Purdue University and a Ph.D. in biochemistry from The Australian National University. He was a post doctoral fellow at Stanford University from 1980 to 1982. |
Gary Pace |
Dr. Gary W. Pace, Ph.D., serves as an Independent Director of Pacira Pharmaceuticals Inc., since June 2008. He is currently founder and chairman of the privately held Sova Pharmaceuticals Inc., founded in 2010, founder, director and consultant to QRxPharma Ltd. (ASX:QRX) founded in 2001, a director of ResMed (NYSE:RMD) since 1994 and Transition Therapeutics Inc. (CDNX:TTH) since 2002. He previously served as a member of the board of directors at Celsion Corporation (NASDAQ: CLSN) from 2002 to 2010 and Peplin Inc. (ASX: PLI) from 2004 to 2009. From 2002 to 2007, Dr. Pace was founder, chairman and chief executive officer of QRxPharma Ltd. and from 1995 to 2001, he was president and chief executive officer of RTP Pharma and from 2000 to 2002, Dr. Pace was chairman and chief executive officer of Waratah Pharmaceuticals Inc., a spin-off company from RTP Pharma. From 1993 to 1994, he was the founding president and chief executive officer of Transcend Therapeutics Inc. (formerly Free Radical Sciences Inc.), a biopharmaceutical company. From 1989 to 1993, he was senior vice president of Clintec International, Inc., a Baxter/Nestle joint venture and manufacturer of clinical nutritional products. Dr. Pace holds a B.S. with honors from the University of New South Wales and a Ph.D. from Massachusetts Institute of Technology. |
Andreas Wicki |
Dr. Andreas Wicki, Ph.D., serves as an Independent Director of Pacira Pharmaceuticals Inc., since December 2006. Dr. Wicki is a life sciences entrepreneur and investor with over 16 years of experience in the pharmaceutical and biotechnology industries. Dr. Wicki has been chief executive officer of HBM Partners AG and HBM BioVentures AG since 2001. From 1998 to 2001, Dr. Wicki was the senior vice president of the European Analytical Operations at MDS Inc. From 1990 to 1998, he was co-owner and chief executive officer of ANAWA Laboratorien AG and Clinserve AG, two life sciences contract research companies. Dr. Wicki holds an M.Sc. and Ph.D. in chemistry and biochemistry from the University of Bern, Switzerland. He currently serves on the board of directors of Buchler GmbH, HBM BioPharma India Ltd., HBM BioVentures (Cayman) Ltd., HBM Partners AG, HBM BioCapital Ltd. and PharmaSwiss SA. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Fred Middleton |
-- |
David Stack |
616,550 |
James Scibetta |
377,610 |
Lauren Riker |
-- |
Taunia Markvicka |
-- |
John Pratt |
-- |
Gary Patou |
436,660 |
Laura Brege |
-- |
Luke Evnin |
-- |
Paul Hastings |
-- |
John Longenecker |
-- |
Gary Pace |
-- |
Andreas Wicki |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Fred Middleton |
0 | 0 |
David Stack |
0 | 0 |
James Scibetta |
0 | 0 |
Lauren Riker |
0 | 0 |
Taunia Markvicka |
0 | 0 |
John Pratt |
0 | 0 |
Gary Patou |
0 | 0 |
Laura Brege |
0 | 0 |
Luke Evnin |
0 | 0 |
Paul Hastings |
0 | 0 |
John Longenecker |
0 | 0 |
Gary Pace |
0 | 0 |
Andreas Wicki |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
EVNIN LUKE BASIL |
6,303 | $30.04 |
WICKI ANDREAS |
401 | $30.04 |
EVNIN LUKE BASIL |
108,115 | $30.00 |
WICKI ANDREAS |
15,646 | $30.00 |
EVNIN LUKE BASIL |
2,575 | $30.00 |
WICKI ANDREAS |
6,400 | $30.00 |
EVNIN LUKE BASIL |
37,192 | $2.69 |
PATOU GARY |
10,000 | $1.61 |
PATOU GARY |
10,000 | $30.00 |
EVNIN LUKE BASIL |
3,416 | $29.30 |
EVNIN LUKE BASIL |
10,000 | $30.00 |
WICKI ANDREAS |
34,294 | $30.00 |
WICKI ANDREAS |
600 | $30.00 |
PATOU GARY |
30,000 | $1.61 |
PATOU GARY |
11,300 | $28.82 |
PATOU GARY |
18,700 | $27.75 |
STACK DAVID M |
15,000 | $1.61 |
LONGENECKER JOHN P |
2,000 | $28.49 |
SCIBETTA JAMES S |
10,000 | $1.61 |
SCIBETTA JAMES S |
10,000 | $28.49 |
STACK DAVID M |
15,000 | $28.66 |
LONGENECKER JOHN P |
2,000 | $1.61 |
HBM HEALTHCARE INVESTMENTS CAYMAN LTD |
165,541 | $28.28 |
WICKI ANDREAS |
165,541 | $28.28 |
WICKI ANDREAS |
113,928 | $27.52 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
